Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease.

Licarbazepine is the pharmacologically active metabolite of oxcarbazepine a drug indicated for the treatment of partial seizures and bipolar disorders.

CCF0058981 is a SARS-CoV-2 inhibitor with low nanomolar biochemical inhibition and efficacy in cellular models comparable to that of Remdesivir.